Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 217-421-2 | CAS number: 1843-05-6
Acute Toxicity: dermal
Administrative data
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1965
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with national standard methods with acceptable restrictions
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 965
- Report date:
- 1965
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- yes
- Remarks:
- 7 day post-observation, reporting details
- GLP compliance:
- no
- Test type:
- standard acute method
Test material
- Reference substance name:
- Octabenzone
- EC Number:
- 217-421-2
- EC Name:
- Octabenzone
- Cas Number:
- 1843-05-6
- Molecular formula:
- C21H26O3
- IUPAC Name:
- [2-hydroxy-4-(octyloxy)phenyl](phenyl)methanone
Constituent 1
Test animals
- Species:
- rabbit
- Strain:
- other: albino rabbit, no further data
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- no data
Administration / exposure
- Type of coverage:
- other: occlusive or semicclusive
- Vehicle:
- water
- Details on dermal exposure:
- aqueous paste, held in continous contact with shaved rabbit skin.
- Duration of exposure:
- 24h
- Doses:
- 10000 mg/kg bw
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 7 days
- Frequency of observations and weighing: observations day 1 - 7
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight,organ weights, histopathology, other: - Statistics:
- not required
Results and discussion
Effect levels
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- > 10 000 mg/kg bw
- Mortality:
- none
- Clinical signs:
- other: No clinical signs observed.
- Gross pathology:
- No adverse findings observed.
Applicant's summary and conclusion
- Interpretation of results:
- GHS criteria not met
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
